4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 10
in 16 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
4D Molecular Therapeutics’ EPS trailed consensus in the second fiscal quarter of 2026, reported August 13, 2026, with EPS of -$1.04 versus the -$1.02 estimate (difference -$0.02). Revenue came in at about $3.8 million, with results concentrated in Japan at roughly $3.7 million, while the United States contributed about $0.1 million and grew +500% year over year. On profitability, operating loss was about $77.0 million, and the company posted net income of roughly -$72.9 million, down 33.4% year over year from about -$54.7 million. EPS was down 6.1% from -$0.98 a year ago. For the next period, consensus calls for EPS of -$1.04 on revenue of $3.5 million.
Next report — what to expect
4D Molecular Therapeutics, Inc. (FDMT) reports earnings on November 10, 2026. Wall Street is looking for EPS of -$1.04 on revenue of $3.5 million; for trailing context, revenue rose +25106.7% year over year last quarter. FDMT has beaten EPS in 2 of its 8 most recent quarters, so attention may center on top-line delivery and expense trends.
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. develops genetic medicines through its proprietary adeno-associated virus vector platform as a NASDAQ-listed Biotechnology company, with development efforts concentrated in ophthalmology, cardiology, and pulmonology. It recorded $85.2 million of revenue in FY2025, and its pipeline spans inherited retinal, cardiac, and pulmonary disease programs.
Today's Snapshot
FDMT closed 8.9% below yesterday's close, in line with a weaker sector.
Trading Volume
Below 10d avg (999.4K)
996K
vs S&P 500 Today
Strong Underperformance
-8.34%
Updated: October 23, 2026 at 20:23 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$11.41 - $13.07Sell
- RSI (14)33.15Neutral
- Stochastic %K (14, 3, 3)13.68Buy
- MACD Level (12, 26)-0.57Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.